Abstract. The blood-brain barrier (BBB) influences brain levels of amyloid-␤ (A␤) by transporting A␤ out of the brain (efflux) and by the reabsorption of cerebrospinal fluid (CSF) into the blood stream (bulk flow). In Alzheimer's disease (AD) and normal aging, unknown factors impair A␤ efflux and bulk flow in aging and in AD. These impairments have been proposed as mechanisms by which the A␤ burden in brain can increase. Impairment in A␤ efflux occurs in animal models of AD, including the aged SAMP8 mouse. Here, we show that CSF reabsorption is also reduced by about 50% in SAMP8 mice (p < 0.05). We then determined whether an antisense directed at the A␤ region of the amyloid-␤ protein precursor (A␤PP) and previously shown to decrease brain levels of A␤PP and to reverse the cognitive impairments of the SAMP8 mouse was able to reverse these impairments. We found that the antisense restored both the CSF reabsorption, more than doubling the rate of efflux, and the saturable efflux of A␤. These findings suggest that A␤PP/A␤ itself contributes to the impairments in bulk flow and saturable efflux of A␤ and that reduction of A␤PP/A␤ levels can restore normal function of the BBB.
INTRODUCTION
Amyloid-␤ (A␤) has increasingly emerged as a major candidate in the pathophysiology of Alzheimer's disease (AD) [1] . One mechanism suggested to contribute to the accumulation of A␤ in brain is a defect in its clearance from brain [2] [3] [4] . A␤ is cleared from brain by saturable and nonsaturable mechanisms [5] [6] [7] [8] [9] [10] [11] . Both P-glycoprotein [12, 13] and low density lipoprotein receptor-related protein-1 (LRP) are located at the blood-brain barrier (BBB) [6, 14] and have been suggested to be the saturable transporters for A␤ brain efflux. Histological studies show a decrease in LRP activity in human BBB tissue taken from AD patients [6, 15] , providing a mechanism to explain the decreased efflux of A␤ in AD. Knockdown of LRP function at the BBB results in decreased A␤ efflux, increased A␤ levels in the brain, and cognitive impairments in otherwise normal mice [16] . Nonsaturable efflux occurs with reabsorption of cerebrospinal fluid (CSF), termed bulk flow [17] . Bulk flow is decreased in both AD and healthy aging [18] [19] [20] . Thus, impairments in both the saturable and non-saturable clearance of A␤ from the central nervous system (CNS) could substantially increase the accumulation of A␤ in the CNS. The underlying mechanisms of these impairments are currently unknown.
The SAMP8 mouse, an animal model of AD, has an impaired efflux of A␤ [10] . The SAMP8 strain has a natural mutation that induces with aging an overexpression of amyloid-␤ protein precursor (A␤PP) [21] [22] [23] . The A␤PP also has a single amino acid substitution of an alanine for a valine at position 300 [24] . Although cognitively normal at 2 mo of age, SAMP8 mice develop age-dependent deficits in learning and memory that are severe by 12 mo of age [25] . Cholinergic defects, resistance to the memory enhancing effects of cholinergics, amyloid deposits, alterations in membrane fatty acids and in delta-9-desaturase activity, and oxidative stress to critical proteins have been found in the SAMP8 mouse [26] [27] [28] [29] [30] . Many of these problems, including the cognitive deficits, elevated A␤PP levels, and oxidative stress, can be reversed by treating mice with either antisense directed against the A␤ region of A␤PP or antibody directed against A␤ [21, 23, [31] [32] [33] [34] . The SAMP8 mouse also has a decreased capacity to transport murine A␤ 1-42 at a young age [10] that worsens with age.
The decreased ability of the SAMP8 mice to efflux A␤ could be caused by impairment in the saturable transport, the bulk flow efflux of A␤, or both. The deficit in transport at an early age raises the possibility that early increases in A␤, the mutation in A␤PP, or altered processing of A␤PP may act to impair its own efflux. Here, we addressed two questions: 1) Whether bulk flow is impaired in aged SAMP8 mice; and 2) Whether the impaired brain-to-blood efflux of A␤ could be reversed with antisense directed against A␤PP.
METHODS

Iodination of Aβ and albumin
Five g of carrier-free, recombinant murine A␤ (American Peptide Co, Sunnyvale, CA) was radioactively labeled with 131 I by the chloramine-T method.
The radioactively labeled A␤ (I-A␤) was purified and separated from unincorporated iodine on a column of G-10 Sephadex by eluting 0.1 ml fractions with protein-free, chloride-free phosphate buffer solution. Previous work showed that about 70% of the I-A␤ was in the monomeric form, the form of A␤ most likely to be transported across the BBB [10] . Albumin was also labeled with 131 I by the chloramine-T method and the radioactive albumin (I-Alb) purified on a G-10 Sephadex column.
Measurement of efflux rates
The method has been previously used to quantify efflux of A␤ [35] [36] [37] [38] . Two month old male ICR mice, two month old SAMP8 mice, or twelve month old SAMP8 mice (all from our in-house colonies) were kept on a 12/12 hour light/dark cycle with food and water freely available. They were anesthetized on day of study with 0.15 ml of 40% urethane. The scalp was removed and a hole made into the lateral ventricle, 1.0 mm lateral and 1.0 mm posterior to the bregma, with a 26 gauge needle with a tubing guard which kept the depth of the holes constant (3.0-3.5 mm). Mice received 1.0 l intracerebroventricular (icv) injections containing 5(10 3 ) cpm (about 0.125 ng) of I-A␤ in a lactated Ringer's solution with 1% bovine serum albumin or containing 3(10 5 ) cpm of I-Alb. An inhibitory component to A␤ efflux was tested by including 1 g/mouse of unlabeled A␤ in the injection. Mice were decapitated at 2, 5, 10, and 20 min after injection. For I-Alb, an additional group was decapitated at 30 min. The whole brain was removed, the pituitary and pineal glands were discarded, and the level of residual radioactivity in the whole brain was determined from the counts after 3 min in a gamma counter. The level of radioactivity in whole brain at t = 0 was determined in mice overdosed with anesthetic as previously described [35] . The cpm remaining in the brain was divided by the cpm injected and multiplied by 100 to yield the percent of the injected dose remaining in brain (%Inj/brain). The log of %Inj/brain was regressed against time. A significant correlation between log(%Inj/brain) and time indicated a measurable efflux from brain to blood of the injected substance, with the slope (m) of this relation measuring the rate of efflux.
Antisense treatment regimen
A 42mer phosphorothioate oligodeoxynucleotide antisense directed at A␤ 17-30 (5 ( P = S)GGCGCC TTTGTTCGAACCCACATCTTCAGCAAAGAACA CCAG-3 ) was synthesized by the Midland Certified Reagent Co (Midland, TX) by use of cyanoethyl phosphoramidite chemistry. SAMP8 mice (2 or 12 mo old) were given injections into the tail vein of 0.2 ml saline without (control) or with 6 g of the antisense. Tail vein injections were repeated twice at two week intervals. I-A␤ and I-Alb efflux rates were measured 2 weeks after the final (3rd dose) of antisense.
Statistical analysis
Means are reported with the number of mice used (n) and the standard error of the mean (SEM). Student's t-test was used for comparison of two groups. More than two groups were compared by analysis of variance (ANOVA) followed by Newman-Keuls post test. The p values were reported for relevant statistically significant differences. Regression lines were calculated by the least squares method with the Prism 5.0 program (GraphPad, Inc., San Diego, CA) and the slope (m) with its standard deviation of the mean with its error term, the correlation coefficient (r), the number of points on which the line was based (n) and the p value reported. Slopes were compared by t-test unless there were more than two slopes, which were compared by ANOVA followed by Newman-Keuls post test. The standard deviation of the mean was taken as the standard error term and, because two means (the slope and the intercept) were calculated from the data, n-1 was used as the value for n.
RESULTS
We first compared the efflux of I-Alb in 2 mo old CD-1 mice, 2 mo old SAMP-8 mice, and 12 mo old SAMP8 mice (Fig. 1) . The 12 mo old SAMP8 mice in comparison to either of the 2 mo old strains have increased A␤ burden, cognitive impairment, oxidative stress, decreased acetylcholine, and impaired clearance of A␤ [21, 23, 30, 32, 39, 40] . A statistically significant relation existed between log(%Inj/brain) and time for all three groups, demonstrating a mea- was faster than in either group of SAMP8 (p < 0.05), whereas there was no difference between the two ages of SAMP8 (Fig. 1, bottom panel) .
The effect of antisense treatment on I-Alb efflux from the brains of 12 mo old SAMP8 mice is shown in Fig. 2 . Antisense significantly increased efflux of I-Alb (p < 0.05). Brain weights did not differ between these two groups.
The relation between the log(%Inj/brain) for I-A␤ and time in 2 mo old SAMP8 mice not treated with antisense was not statistically significant, demonstrating a lack of measurable brain-to-blood efflux (Fig. 3, upper  panel) . In mice treated with antisense, the relation between log(%Inj/brain) for I-A␤ and time was statistically significant (m = -0.0099 ± 0.0025, r = 0.818, Lower panel shows that in antisense-treated mice, unlabeled A␤ inhibits I-A␤ efflux from brain (p < 0.05). This confirms that antisense increased A␤ efflux by restoring the saturable mechanism. n = 10, p < 0.005). These lines were significantly different by t-test (p < 0.05). As a control, antisense was injected 5 min before an icv injection of I-A␤ in 2 mo old CD-1 mice. Antisense produced no change in the log(%Inj/brain) for I-A␤ in brains harvested 15 min after the icv injection.
To determine whether the increased efflux of I-A␤ treatment involved restoration of the saturable A␤ transporter, we included unlabeled A␤ (1 g/mouse) in the injection of 2 mo old SAMP8 mice treated with antisense. The t-test showed a significant inhibition (p < 0.05) in efflux with unlabeled A␤ (Fig. 3,  lower panel) . This demonstrates that the increase in efflux of A␤ induced by antisense was caused by the re-establishment of the saturable process.
DISCUSSION
Impaired efflux of A␤ by saturable and nonsaturable mechanisms could contribute to the A␤ burden in brains of AD patients. The major findings of the current study are i) bulk flow is decreased in the SAMP8 mouse, ii) antisense directed against A␤PP reverses the impairment in brain-to-blood efflux of A␤ in the SAMP8 mouse, iii) antisense restores the saturable efflux of A␤. These findings suggest that A␤ itself is responsible for both the impairment of its own transporter and for inhibition of bulk flow.
CSF slowly enters the blood stream by reabsorption at the arachnoid villi and the cribriform plate [41] . This reabsorption is termed bulk flow and its rate is classically measured by the use of radioactively labeled albumin as we did here [17] . The slow, nonsaturable reabsorption of CSF, termed bulk flow, could also allow toxic substances other than A␤ to accumulate by decreasing their clearance from the brain. Decreased bulk flow can also explain the higher CSF/serum ratios for albumin often noted in AD patients [20] and often assumed to be BBB disruption. Restoration of the clearance of CSF, and especially restoration of the clearance of A␤, would likely improve cognitive function in models of A␤ toxicity. As such, correction of decreased bulk flow has been suggested as a treatment of AD [19] . The current results are consistent with this conjecture, as we have previously found that this antisense improves cognitive functioning in the SAMP8 mouse [10, 21, 31] .
The saturable clearance of A␤ and its impairment in AD is well documented by several laboratories [5-7, 10, 42] . Two BBB transporters have been implicated in A␤ efflux, LRP-1 and P-gp [6, 7, 12, 13] . Inhibition of LRP-1 in young, normal mice results in decreased efflux of A␤ from brain, increased A␤ levels in brain, and cognitive impairments [16] . Here, we showed that treatment of SAMP8 mice not only increased the rate of I-A␤ efflux, but that the increase was attributable to a process inhibited by unlabeled A␤. This inhibition by unlabeled A␤ demonstrates that the increased flux of radioactivity was not explicable only by an increase in bulk flow or other transporters such as that for free iodine.
The antisense used here is a phosphorothioated molecule directed at A␤ [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . It decreases A␤PP and A␤ levels in the brains of SAMP8 mice [21, 34] . The antisense does not affect the levels of other substances and its reverse antisense is without effect [21, 43] . This antisense is stable in blood with a long residence time in blood and peripheral tissues [31] . It is transported across the blood-brain barrier by a saturable system and can reverse the cognitive impairments and oxidative stresses found in the SAMP8 mouse after ICV or IV administration [21, 31, 34] . The method used to assess efflux is well described and has been widely used to measure brain-to-blood transport [35, 36, [44] [45] [46] [47] . Because the material to be assessed is injected into the lateral ventricle of the brain, transporters at both periventricular microvasculature and choroid plexus as well as bulk flow are assessed [48] [49] [50] . The rates calculated by this method are not indices, but measure efflux rates that are identical to those assessed by the gold standard of rate of appearance in blood [51] . We assessed A␤ here, rather than A␤ , as it is considered to be the more toxic form of A␤.
The causes for the decrease in bulk flow and saturable efflux of A␤ in normal aging or AD are unknown. The results presented here suggest that A␤PP or A␤ itself is responsible for this decrease in bulk flow as well as the decrease in A␤ efflux. A␤ could affect BBB function through several mechanisms. For example, A␤ can cause formation of ion channels and induce oxidative stress. Bulk flow is a hydrostatic process that depends on CSF formation and requires the ion magnesium and altered ion transport and oxidative stress have been proposed to explain age-related decreases in CSF turnover [52] . Oxidative stress could result in damage to A␤ transporters as well as to the cellular machinery responsible for bulk flow. SAMP8 mice show increased oxidative stress which is reversed with antisense to A␤ [34] . Furthermore, the antioxidant alpha lipoic acid reverses both the cognitive impairments and the oxidative stress seen in the SAMP8 [40, 53] . These mechanisms are consistent with in vitro work showing that A␤ can enhance proteasome-dependent degradation of LRP, one of the candidate transporters for A␤ [54] . Additionally, A␤ can interfere with cytoskeletal arrangement which is critical to the functioning of the BBB [55] .
In conclusion, we found that bulk flow (CSF reabsorption) is impaired in the aged SAMP8 mouse, an animal model of AD. Treatment with antisense directed at A␤ region of A␤PP not only restores bulk flow, but also restores the previously described deficit in the saturable efflux of A␤. These results suggest that among the CNS lesions induced by A␤ are two deficits in BBB function: impaired reabsorption of CSF and impaired saturable clearance of A␤. Both of these deficits would contribute to the accumulation by the CNS of toxic materials, including A␤.
